{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:57:44Z","timestamp":1792616264495,"version":"4.5.0"},"reference-count":119,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Ivermectin is a broad-spectrum antiparasitic drug with anti-inflammatory, anti-viral, anti-bacterial, and anti-tumor effects. In this review, we discuss the history, pharmacology, multimodal actions, indications in dermatology and tropical medicine, therapeutic and prophylactic use of ivermectin in COVID-19, safety, adverse effects, special considerations, and drug interactions of ivermectin.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/idoj.idoj_298_21","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T09:21:26Z","timestamp":1637054486000},"page":"500-514","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":25,"title":["Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19"],"prefix":"10.4103","volume":"12","author":[{"given":"Sinu Rose","family":"Mathachan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kabir","family":"Sardana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananta","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20240828","doi-asserted-by":"crossref","first-page":"674","DOI":"10.4103\/ijdvl.IJDVL_840_18","article-title":"Wonder drug for worms. A review of three decades of ivermectin use in dermatology","volume":"85","author":"Gowtham","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R3-3-20240828","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1111\/j.1365-4632.2004.02253.x","article-title":"Ivermectin: Pharmacology and application in dermatology","volume":"44","author":"Dourmishev","year":"2005","journal-title":"Int J Dermatol"},{"key":"R4-3-20240828","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(82)91026-1","article-title":"Efficacy and tolerance of ivermectin in human onchocerciasis","volume":"2","author":"Aziz","year":"1982","journal-title":"Lancet"},{"key":"R7-3-20240828","doi-asserted-by":"crossref","first-page":"13030\/qt1kq4p7pp","DOI":"10.5070\/D3229032496","article-title":"Clinical applications of topical ivermectin in dermatology","volume":"22","author":"Zargari","year":"2016","journal-title":"Dermatol Online J"},{"key":"R8-3-20240828","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1177\/009127002237994","article-title":"Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects","volume":"42","author":"Guzzo","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"R9-3-20240828","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1208\/s12248-007-9000-9","article-title":"The pharmacokinetics and interactions of ivermectin in humans--A mini-review","volume":"10","author":"Gonz\u00e1lez Canga","year":"2008","journal-title":"AAPS J"},{"key":"R10-3-20240828","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.2196\/resprot.6617","article-title":"Efficacy and safety of high-dose ivermectin for reducing malaria transmission (IVERMAL): Protocol for a double-blind, randomized, placebo-controlled, dose-finding trial in Western Kenya","volume":"5","author":"Smit","year":"2016","journal-title":"JMIR Res Protoc"},{"key":"R11-3-20240828","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4269\/ajtmh.1988.39.480","article-title":"Ivermectin in loiasis and concomitant O. volvulus and M. perstans infections","volume":"39","author":"Richard-Lenoble","year":"1988","journal-title":"Am J Trop Med Hyg"},{"key":"R12-3-20240828","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12936-017-1801-4","article-title":"Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety","volume":"16","author":"Chaccour","year":"2017","journal-title":"Malar J"},{"key":"R13-3-20240828","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/BF00316107","article-title":"Ivermectin binds avidly to plasma proteins","volume":"39","author":"Klotz","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-3-20240828","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1001\/archderm.138.12.1618","article-title":"Rapid and preferential sebum secretion of ivermectin: A new factor that may determine drug responsiveness in patients with scabies","volume":"138","author":"Haas","year":"2002","journal-title":"Arch Dermatol"},{"key":"R15-3-20240828","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4269\/ajtmh.2007.76.1153","article-title":"Pharmacokinetics of azithromycin and the combination of ivermectin and albendazole when administered alone and concurrently in healthy volunteers","volume":"76","author":"Amsden","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"R17-3-20240828","doi-asserted-by":"crossref","first-page":"5867","DOI":"10.1093\/emboj\/16.19.5867","article-title":"avr-15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans","volume":"16","author":"Dent","year":"1997","journal-title":"EMBO J"},{"key":"R18-3-20240828","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.pt.2020.10.005","article-title":"Ivermectin: An anthelmintic, an insecticide, and much more","volume":"37","author":"Martin","year":"2021","journal-title":"Trends Parasitol"},{"key":"R19-3-20240828","first-page":"100","article-title":"Clinical pharmacology of ivermectin","volume":"189","author":"Bennett","year":"1986","journal-title":"J Am Vet Med Assoc"},{"key":"R20-3-20240828","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/archderm.135.12.1549","article-title":"Ivermectin: A few caveats are warranted before initiating therapy for scabies","volume":"135","author":"Burkhart","year":"1999","journal-title":"Arch Dermatol"},{"key":"R21-3-20240828","doi-asserted-by":"crossref","first-page":"605","DOI":"10.4103\/0378-6323.100571","article-title":"Comparative efficacy and safety of topical permethrin, topical ivermectin, and oral ivermectin in patients of uncomplicated scabies","volume":"78","author":"Chhaiya","year":"2012","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"R22-3-20240828","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5455\/2319-2003.ijbcp002712","article-title":"Ivermectin: Pharmacology and therapeutic applications","volume":"1","author":"Chhaiya","year":"2012","journal-title":"Int J Basic Clin Pharmacol"},{"key":"R23-3-20240828","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10158-007-0050-6","article-title":"Molecular characterisation of a pH-gated chloride channel from Sarcoptes scabiei","volume":"7","author":"Mounsey","year":"2007","journal-title":"Invert Neurosci"},{"key":"R24-3-20240828","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1017\/S0022149X1400039X","article-title":"The Conqueror Worm: Recent advances with cholinergic anthelmintics and techniques excite research for better therapeutic drugs","volume":"89","author":"Martin","year":"2015","journal-title":"J Helminthol"},{"key":"R25-3-20240828","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1186\/s40064-016-2819-8","article-title":"The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: A network meta-analysis","volume":"5","author":"Siddiqui","year":"2016","journal-title":"Springerplus"},{"key":"R26-3-20240828","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/jdv.14437","article-title":"Dual anti-inflammatory and anti-parasitic action of topical ivermectin 1% in papulopustular rosacea","volume":"31","author":"Schaller","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R27-3-20240828","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00011-011-0307-8","article-title":"Anti-inflammatory effects of ivermectin in mouse model of allergic asthma","volume":"60","author":"Yan","year":"2011","journal-title":"Inflamm Res"},{"key":"R28-3-20240828","first-page":"76","article-title":"Our scabies treatment is archaic, but ivermectin has arrived","volume":"37","author":"Burkhart","year":"1998","journal-title":"Int J Dermatol"},{"key":"R29-3-20240828","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1128\/AAC.01696-12","article-title":"Anthelmintic avermectins kill Mycobacterium tuberculosis, including multidrug-resistant clinical strains","volume":"57","author":"Lim","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-3-20240828","doi-asserted-by":"crossref","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res"},{"key":"R31-3-20240828","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/1087057110390360","article-title":"An AlphaScreen\u00ae-based assay for high-throughput screening for specific inhibitors of nuclear import","volume":"16","author":"Wagstaff","year":"2011","journal-title":"J Biomol Screen"},{"key":"R32-3-20240828","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem J"},{"key":"R33-3-20240828","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.antiviral.2013.10.004","article-title":"Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication","volume":"100","author":"Lundberg","year":"2013","journal-title":"Antiviral Res"},{"key":"R34-3-20240828","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.antiviral.2012.06.008","article-title":"Nuclear trafficking of proteins from RNA viruses: Potential target for antivirals?","volume":"95","author":"Caly","year":"2012","journal-title":"Antiviral Res"},{"key":"R35-3-20240828","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/acs.jmedchem.0c00033","article-title":"Molecular design and synthesis of ivermectin hybrids targeting hepatic and erythrocytic stages of plasmodium parasites","volume":"63","author":"Singh","year":"2020","journal-title":"J Med Chem"},{"key":"R36-3-20240828","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S0140-6736(18)32321-3","article-title":"Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): A cluster-randomised trial","volume":"393","author":"Foy","year":"2019","journal-title":"Lancet"},{"key":"R37-3-20240828","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","article-title":"Ivermectin-Old drug, new tricks?","volume":"33","author":"Laing","year":"2017","journal-title":"Trends Parasitol"},{"key":"R38-3-20240828","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s13167-020-00209-y","article-title":"Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes","volume":"11","author":"Li","year":"2020","journal-title":"EPMA J"},{"key":"R39-3-20240828","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.6308762","article-title":"Ivermectin: A potent new antiparasitic agent","volume":"221","author":"Campbell","year":"1983","journal-title":"Science"},{"key":"R41-3-20240828","first-page":"Cd012994","article-title":"Ivermectin and permethrin for treating scabies","volume":"4","author":"Rosumeck","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R42-3-20240828","first-page":"1","article-title":"Sexually transmitted diseases treatment guidelines, 2010","volume":"59","author":"Workowski","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"R43-3-20240828","first-page":"719","article-title":"Comparison of oral ivermectin vs. lindane lotion 1% for the treatment of scabies","volume":"38","author":"Mohebbipour","year":"2013","journal-title":"Clin Exp Dermatol"},{"key":"R44-3-20240828","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/QCO.0b013e32835e1d57","article-title":"Treatment and control of scabies","volume":"26","author":"Mounsey","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"R45-3-20240828","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/bjd.12454","article-title":"Treatment of scabies with oral ivermectin in 15 infants: A retrospective study on tolerance and efficacy","volume":"169","author":"B\u00e9court","year":"2013","journal-title":"Br J Dermatol"},{"key":"R46-3-20240828","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1056\/NEJM199503023320917","article-title":"Ivermectin for crusted (Norwegian) scabies","volume":"332","author":"Aubin","year":"1995","journal-title":"N Engl J Med"},{"key":"R47-3-20240828","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJM199507063330105","article-title":"The treatment of scabies with ivermectin","volume":"333","author":"Meinking","year":"1995","journal-title":"N Engl J Med"},{"key":"R48-3-20240828","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(99)09458-1","article-title":"Scabies and pediculosis","volume":"355","author":"Chosidow","year":"2000","journal-title":"Lancet"},{"key":"R49-3-20240828","first-page":"233","article-title":"An epidemiologic and therapeutic reassessment of scabies","volume":"65","author":"Burkhart","year":"2000","journal-title":"Cutis"},{"key":"R50-3-20240828","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jinf.2004.08.033","article-title":"Crusted scabies: Clinical and immunological findings in seventy-eight patients and a review of the literature","volume":"50","author":"Roberts","year":"2005","journal-title":"J Infect"},{"key":"R51-3-20240828","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1500987","article-title":"Mass drug administration for scabies control in a population with endemic disease","volume":"373","author":"Romani","year":"2015","journal-title":"N Engl J Med"},{"key":"R52-3-20240828","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa1200107","article-title":"Topical 0.5% ivermectin lotion for treatment of head lice","volume":"367","author":"Pariser","year":"2012","journal-title":"N Engl J Med"},{"key":"R53-3-20240828","first-page":"316","article-title":"Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: Results of two randomized, double-blind, vehicle-controlled pivotal studies","volume":"13","author":"Stein","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"R54-3-20240828","first-page":"88","article-title":"Demodecicose profuse au cours d\u2019une leukemie aigue lymphoblastique chez 2 enfants. Efficacite de l\u2019ivermectine","volume":"127","author":"Rylojad","year":"2000","journal-title":"Ann Dermatol Venereol"},{"key":"R55-3-20240828","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1473-3099(08)70099-9","article-title":"Effect of single-dose ivermectin on Onchocerca volvulus: A systematic review and meta-analysis","volume":"8","author":"Bas\u00e1\u00f1ez","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R56-3-20240828","doi-asserted-by":"crossref","first-page":"657","DOI":"10.4269\/ajtmh.1990.43.657","article-title":"Effects of multiple monthly doses of ivermectin on adult Onchocerca volvulus","volume":"43","author":"Duke","year":"1990","journal-title":"Am J Trop Med Hyg"},{"key":"R57-3-20240828","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13071-020-04126-x","article-title":"Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually","volume":"13","author":"Campillo","year":"2020","journal-title":"Parasit Vectors"},{"key":"R58-3-20240828","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1086\/657063","article-title":"Use of high-dose, twice-yearly albendazole and ivermectin to suppress Wuchereria bancrofti microfilarial levels","volume":"51","author":"Dembele","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R59-3-20240828","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/00034983.1992.11812664","article-title":"Ivermectin for the treatment of periodic malayan filariasis: A study of efficacy and side effects following a single oral dose and retreatment at six months","volume":"86","author":"Shenoy","year":"1992","journal-title":"Ann Trop Med Parasitol"},{"key":"R60-3-20240828","doi-asserted-by":"crossref","first-page":"e0009294","DOI":"10.1371\/journal.pntd.0009294","article-title":"An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia","volume":"15","author":"Supali","year":"2021","journal-title":"PLoS Negl Trop Dis"},{"key":"R61-3-20240828","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1473-3099(19)30289-0","article-title":"Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): A multicentre, open-label, phase 3, randomised controlled superiority trial","volume":"19","author":"Buonfrate","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"R62-3-20240828","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4269\/ajtmh.1996.55.477","article-title":"A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children","volume":"55","author":"Marti","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"R63-3-20240828","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4269\/ajtmh.1993.49.641","article-title":"A randomized trial of ivermectin versus albendazole for the treatment of cutaneous larva migrans","volume":"49","author":"Caumes","year":"1993","journal-title":"Am J Trop Med Hyg"},{"key":"R64-3-20240828","first-page":"47","article-title":"Therapeutic trial with ivermectin in loiasis with medium and high microfilaremia","volume":"71","author":"Carme","year":"1991","journal-title":"Ann Soc Belg Med Trop"},{"key":"R65-3-20240828","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1007\/s12070-018-1444-y","article-title":"Ivermectin: A novel method of treatment of nasal and nasopharyngeal myiasis","volume":"71","author":"Sayeed","year":"2019","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"R66-3-20240828","first-page":"650","article-title":"Double-dose ivermectin vs albendazole for the treatment of gnathostomiasis","volume":"36","author":"Nontasut","year":"2005","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"R67-3-20240828","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijid.2020.11.191","article-title":"A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness","volume":"103","author":"Ahmed","year":"2021","journal-title":"Int J Infect Dis"},{"key":"R68-3-20240828","first-page":"828","article-title":"Ivermectin treatment may improve the prognosis of patients with COVID-19","volume":"6","author":"Khan","year":"2020","journal-title":"Arch Bronconeumol"},{"key":"R69-3-20240828","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.chest.2020.10.009","article-title":"Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The Ivermectin in COVID Nineteen Study","volume":"159","author":"Rajter","year":"2021","journal-title":"Chest"},{"key":"R70-3-20240828","doi-asserted-by":"crossref","first-page":"e0247163","DOI":"10.1371\/journal.pone.0247163","article-title":"Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study","volume":"16","author":"Behera","year":"2021","journal-title":"PLoS One"},{"key":"R73-3-20240828","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa0905471","article-title":"Oral ivermectin versus malathion lotion for difficult-to-treat head lice","volume":"362","author":"Chosidow","year":"2010","journal-title":"N Engl J Med"},{"key":"R74-3-20240828","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jmedent\/45.1.75","article-title":"A new ivermectin formulation topically kills permethrin-resistant human head lice (Anoplura: Pediculidae)","volume":"45","author":"Strycharz","year":"2008","journal-title":"J Med Entomol"},{"key":"R75-3-20240828","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2583.2011.01097.x","article-title":"Brief exposures of human body lice to sublethal amounts of ivermectin over-transcribes detoxification genes involved in tolerance","volume":"20","author":"Yoon","year":"2011","journal-title":"Insect Mol Biol"},{"key":"R76-3-20240828","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1086\/499279","article-title":"Oral ivermectin in the treatment of body lice","volume":"193","author":"Foucault","year":"2006","journal-title":"J Infect Dis"},{"key":"R77-3-20240828","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.13408","article-title":"Superiority of ivermectin 1% cream over metronidazole 0\u00b775% cream in treating inflammatory lesions of rosacea: A randomized, investigator-blinded trial","volume":"172","author":"Taieb","year":"2015","journal-title":"Br J Dermatol"},{"key":"R78-3-20240828","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jaad.2016.10.034","article-title":"Ivermectin therapy for papulopustular rosacea and periorificial dermatitis in children: A series of 15 cases","volume":"76","author":"Noguera-Morel","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R79-3-20240828","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/0019-5154.123498","article-title":"Human demodex mite: The versatile mite of dermatological importance","volume":"59","author":"Rather","year":"2014","journal-title":"Indian J Dermatol"},{"key":"R80-3-20240828","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-4632.2004.02279.x","article-title":"Cutaneous onchocercoma","volume":"43","author":"Okulicz","year":"2004","journal-title":"Int J Dermatol"},{"key":"R81-3-20240828","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/00034983.1997.11813154","article-title":"The entry of ivermectin and suramin into Onchocerca ochengi nodules","volume":"91","author":"Cross","year":"1997","journal-title":"Ann Trop Med Parasitol"},{"key":"R82-3-20240828","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1001\/jama.1988.03720210040026","article-title":"Ivermectin for the treatment of Wuchereria bancrofti filariasis. Efficacy and adverse reactions","volume":"259","author":"Kumaraswami","year":"1988","journal-title":"JAMA"},{"key":"R83-3-20240828","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0035-9203(92)90312-Z","article-title":"Long-term suppression of microfilaraemia following ivermectin treatment","volume":"86","author":"Eberhard","year":"1992","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R84-3-20240828","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.trstmh.2006.12.004","article-title":"Impact of 10 years of diethylcarbamazine and ivermectin mass administration on infection and transmission of lymphatic filariasis","volume":"101","author":"Ramaiah","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R85-3-20240828","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis","volume":"62","author":"Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R86-3-20240828","doi-asserted-by":"crossref","first-page":"bcr2017223138","DOI":"10.1136\/bcr-2017-223138","article-title":"Successful use of subcutaneous ivermectin for the treatment of Strongyloides stercoralis hyperinfection in the setting of small bowel obstruction and paralytic ileus in the immunocompromised population","volume":"2018","author":"Zeitler","year":"2018","journal-title":"BMJ Case Rep"},{"key":"R87-3-20240828","doi-asserted-by":"crossref","first-page":"911","DOI":"10.4269\/ajtmh.2005.73.911","article-title":"Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis","volume":"73","author":"Turner","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"R89-3-20240828","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4269\/ajtmh.1998.58.458","article-title":"Short- and long-term action of multiple doses of ivermectin on loiasis microfilaremia","volume":"58","author":"Kombila","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"R90-3-20240828","doi-asserted-by":"crossref","first-page":"100582","DOI":"10.1016\/j.eclinm.2020.100582","article-title":"Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa","volume":"28","author":"Chesnais","year":"2020","journal-title":"EClinicalMedicine"},{"key":"R91-3-20240828","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.actatropica.2008.03.007","article-title":"A randomized, double-blind, multicenter clinical trial on the efficacy of ivermectin against intestinal nematode infections in China","volume":"106","author":"Wen","year":"2008","journal-title":"Acta Trop"},{"key":"R92-3-20240828","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4269\/ajtmh.1999.60.479","article-title":"Assessment of combined ivermectin and albendazole for treatment of intestinal helminth and Wuchereria bancrofti infections in Haitian schoolchildren","volume":"60","author":"Beach","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"R93-3-20240828","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1475-2875-12-153","article-title":"Ivermectin to reduce malaria transmission: A research agenda for a promising new tool for elimination","volume":"12","author":"Chaccour","year":"2013","journal-title":"Malar J"},{"key":"R94-3-20240828","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.antiviral.2018.09.010","article-title":"Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo","volume":"159","author":"Lv","year":"2018","journal-title":"Antiviral Res"},{"key":"R95-3-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/scipharm88030036","article-title":"Antiviral activity of ivermectin against SARS-CoV-2: An old-fashioned dog with a new trick\u2014A literature review","volume":"88","author":"Mudatsir","year":"2020","journal-title":"Sci Pharm"},{"key":"R97-3-20240828","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1124\/mol.53.2.283","article-title":"Ivermectin: A positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor","volume":"53","author":"Krause","year":"1998","journal-title":"Mol Pharmacol"},{"key":"R98-3-20240828","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5802\/crbiol.8","article-title":"A nicotinic hypothesis for Covid-19 with preventive and therapeutic implications","volume":"343","author":"Changeux","year":"2020","journal-title":"C R Biol"},{"key":"R99-3-20240828","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/j.ijbiomac.2020.09.098","article-title":"Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach","volume":"163","author":"Parvez","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"R100-3-20240828","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1085\/jgp.200308986","article-title":"Mechanism of ivermectin facilitation of human P2\u00d74 receptor channels","volume":"123","author":"Priel","year":"2004","journal-title":"J Gen Physiol"},{"key":"R101-3-20240828","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13555-017-0176-3","article-title":"Topical treatment of rosacea with ivermectin inhibits gene expression of cathelicidin innate immune mediators, LL-37 and KLK5, in reconstructed and ex vivo skin models","volume":"7","author":"Thibaut de M\u00e9nonville","year":"2017","journal-title":"Dermatol Ther (Heidelb"},{"key":"R102-3-20240828","doi-asserted-by":"crossref","first-page":"AB172","DOI":"10.1016\/j.jaad.2015.02.705","article-title":"MeTC7, a novel vitamin D receptor (VDR) antagonist, induces cytotoxicity in metastatic melanoma cell lines and inhibits importin-mediated VDR nuclear transport and signaling: 1629","volume":"72","author":"Han","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R103-3-20240828","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00210-020-01902-5","article-title":"Ivermectin, antiviral properties and COVID-19: A possible new mechanism of action","volume":"393","author":"Rizzo","year":"2020","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R105-3-20240828","doi-asserted-by":"crossref","first-page":"e0242184","DOI":"10.1371\/journal.pone.0242184","article-title":"Lack of efficacy of standard doses of ivermectin in severe COVID-19 patients","volume":"15","author":"Camprub\u00ed","year":"2020","journal-title":"PLoS One"},{"key":"R107-3-20240828","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12879-021-06104-9","article-title":"Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients","volume":"21","author":"Okumu\u015f","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R109-3-20240828","doi-asserted-by":"crossref","first-page":"100720","DOI":"10.1016\/j.eclinm.2020.100720","article-title":"The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial","volume":"32","author":"Chaccour","year":"2021","journal-title":"EClinicalMedicine"},{"key":"R112-3-20240828","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.toxrep.2021.03.003","article-title":"Use of ivermectin in the treatment of Covid-19: A pilot trial","volume":"8","author":"Pott-Junior","year":"2021","journal-title":"Toxicol Rep"},{"key":"R113-3-20240828","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/0885066620973585","article-title":"Clinical and scientific rationale for the \u201cMATH+\u201d hospital treatment protocol for COVID-19","volume":"36","author":"Kory","year":"2021","journal-title":"J Intensive Care Med"},{"key":"R114-3-20240828","doi-asserted-by":"crossref","first-page":"106248","DOI":"10.1016\/j.ijantimicag.2020.106248","article-title":"A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin","volume":"57","author":"Hellwig","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R115-3-20240828","doi-asserted-by":"crossref","first-page":"462","DOI":"10.18433\/jpps31457","article-title":"Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis","volume":"23","author":"Padhy","year":"2020","journal-title":"J Pharm Pharm Sci"},{"key":"R116-3-20240828","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41429-020-0336-z","article-title":"Ivermectin: A systematic review from antiviral effects to COVID-19 complementary regimen","volume":"73","author":"Heidary","year":"2020","journal-title":"J Antibiot (Tokyo"},{"key":"R117-3-20240828","doi-asserted-by":"crossref","first-page":"e0006020","DOI":"10.1371\/journal.pntd.0006020","article-title":"Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers","volume":"12","author":"Mu\u00f1oz","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"R119-3-20240828","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/0140-6736(90)91253-7","article-title":"Safety of and compliance with community-based ivermectin therapy","volume":"335","author":"Pacqu\u00e9","year":"1990","journal-title":"Lancet"},{"key":"R120-3-20240828","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1186\/1475-2883-2-S1-S8","article-title":"Ivermectin: Does P-glycoprotein play a role in neurotoxicity?","volume":"2","author":"Edwards","year":"2003","journal-title":"Filaria J"},{"key":"R121-3-20240828","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/jac\/dkz524","article-title":"Safety of high-dose ivermectin: A systematic review and meta-analysis","volume":"75","author":"Navarro","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"R123-3-20240828","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-4362.2000.00990.x","article-title":"Management of endemic outbreaks of scabies with allethrin, permethrin, and ivermectin","volume":"39","author":"Paasch","year":"2000","journal-title":"Int J Dermatol"},{"key":"R125-3-20240828","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4269\/ajtmh.17-0042","article-title":"Serious neurological adverse events after ivermectin-Do they occur beyond the indication of onchocerciasis?","volume":"98","author":"Chandler","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"R126-3-20240828","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijantimicag.2016.01.001","article-title":"Synergistic activity of antibiotics combined with ivermectin to kill body lice","volume":"47","author":"Sangar\u00e9","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R127-3-20240828","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002280000120","article-title":"Do alcoholic beverages enhance availability of ivermectin?","volume":"56","author":"Shu","year":"2000","journal-title":"Eur J Clin Pharmacol"},{"key":"R128-3-20240828","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0009-9236(03)90702-8","article-title":"Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers","volume":"73","author":"Vanapalli","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R129-3-20240828","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0304-4017(95)00909-4","article-title":"The prevalence of anthelmintic resistance in nematode parasites of sheep in southern Latin America: General overview","volume":"62","author":"Waller","year":"1996","journal-title":"Vet Parasitol"},{"key":"R130-3-20240828","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0166-6851(97)00215-6","article-title":"Ivermectin resistance in nematodes may be caused by alteration of P-glycoprotein homolog","volume":"91","author":"Xu","year":"1998","journal-title":"Mol Biochem Parasitol"},{"key":"R131-3-20240828","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1179\/000349804225003253","article-title":"An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana","volume":"98","author":"Awadzi","year":"2004","journal-title":"Ann Trop Med Parasitol"},{"key":"R132-3-20240828","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.ijantimicag.2018.07.005","article-title":"Mutations in GluCl associated with field ivermectin-resistant head lice from Senegal","volume":"52","author":"Amanzougaghene","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R133-3-20240828","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/ijd.13999","article-title":"Tackling scabies: Novel agents for a neglected disease","volume":"57","author":"Gopinath","year":"2018","journal-title":"Int J Dermatol"},{"key":"R134-3-20240828","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijpara.2008.06.009","article-title":"Increased expression of ABC transport proteins is associated with ivermectin resistance in the model nematode Caenorhabditis elegans","volume":"39","author":"James","year":"2009","journal-title":"Int J Parasitol"},{"key":"R135-3-20240828","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/0035-9203(93)90146-H","article-title":"Absence of any adverse effect of inadvertent ivermectin treatment during pregnancy","volume":"87","author":"Chippaux","year":"1993","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"R136-3-20240828","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/bjd.18369","article-title":"Ivermectin safety in infants and children under 15 kg treated for scabies: A multicentric observational study","volume":"182","author":"Levy","year":"2020","journal-title":"Br J Dermatol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_298_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:12:44Z","timestamp":1787166764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_298_21"}},"subtitle":["An Update on Pharmacology, Uses, Proven and Varied Proposed Mechanistic Action"],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":119,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_298_21","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}